Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
A frozen and thawed vial of tirzepatide or semaglutide should be discarded immediately
Lipo C Zepbound Timing: Standard Weekly Protocol The most common error is injecting both on the same day "to get it over with." This increases peak injection site inflammation, raises the risk of localized hematoma formation, and makes it impossible to distinguish which compound caused a reaction if side effects occur
They will also monitor your symptoms to see how they respond
doi: 10.1038/jcbfm.2015.17 84 LarssonMLietzauGNathansonDstensonCGMallardCJohanssonMEet al